| Similar Articles |
|---|
 |
The Motley Fool
April 24, 2009
Robert Steyer |
Nothing to CRO About The good times have stopped rolling for Contract research organizations, as they warn of unexpected contract cancellations and reduced demand for services.   |
The Motley Fool
July 22, 2009
Robert Steyer |
Canaries in the Drug Coal Mine Contract research organizations like Pharmaceutical Product Development and ICON reflect an ailing drug industry. |
The Motley Fool
March 6, 2009
Brian Orelli |
For Drug Companies, R&D Is Spelled C-R-O It seems likely that more and more pharma companies will try to get more bang for their bucks by spending them on research and development done outside the company, outsourcing it to clinical research organizations. |
The Motley Fool
August 1, 2008
Brian Orelli |
Recession Schmession, This Industry Is On Fire Contract research organizations do pre-clinical research and run clinical trials for drug developers on the cheap. With pharmaceutical companies cutting back on costs, CROs are in the perfect position to benefit. |
The Motley Fool
October 31, 2006
Brian Gorman |
Kendle's New Risk The drug development services company continues to deliver, but new debt poses some risk to future earnings. In the near term, investors could be in for a bumpy ride. |
The Motley Fool
July 30, 2009
Robert Steyer |
Covance Advances Covance latest results produce more optimism than did some of its contract research peers. |
The Motley Fool
July 27, 2011
Michael Olsen |
Rising Stars Buy: Icon Icon, the fourth-largest CRO, sits among the global elite and makes for a healthy investment. |
The Motley Fool
November 30, 2007
Brian Orelli |
Clinical Trial Failures Don't Bother These Companies Contract research organizations, outsourcing companies hired by pharmaceutical and biotech companies to run pre-clinical tests and clinical trials for them, succeed even when drugs fail, and more work may be coming their way. |
The Motley Fool
November 1, 2005
Brian Gorman |
Kendle's Resurgence Can the contract pharmaceutical researcher continue its growth without more acquisitions? Despite the vibrant growth and its operational progress, Kendle still is at a disadvantage to larger rivals like Charles River Laboratories and PPD. |
The Motley Fool
February 15, 2005
Brian Gorman |
Kendle Grows With Client Base The contract drug research company shares surged as the firm showed signs of new life. |
Pharmaceutical Executive
April 1, 2009
David Zuckerman |
Make a Match Big Pharma is finally making a commitment to partner-based outsourcing. |
The Motley Fool
August 13, 2009
Brian Orelli |
WuXi: Making Money Both Ways Cost-cutting and revenue growth make pharma outsourcing specialist WuXi a looker for the year. |
Bio-IT World
January 13, 2003
Mark D. Uehling |
Powerhouse CRO (Slowly) Goes Electronic Unhappy customers at Quintiles -- the world's largest CRO (contract research organization) -- are rare. It kept plugging away at the startup process, redesigning it from scratch. Now starting electronic trials takes no longer than paper ones. |
The Motley Fool
April 28, 2006
Brian Gorman |
Kendle Stays Hot The small contract research outfit seems like a safe bet in the near term, but investors should closely monitor the firm's performance. |
The Motley Fool
October 29, 2009
Robert Steyer |
Pharma Researchers Need a Cure As the industry changes, Pharmaceutical Product Development and Parexel International struggle. |
The Motley Fool
August 25, 2006
Brian Gorman |
California's Drug Demands As the pressure grows on drugmakers from legislation, growth and consolidation in the outsourcing business seem likely. |
The Motley Fool
February 14, 2006
Brian Gorman |
Kendle's on Solid Ground The contract research services outfit is on track for another good year. Investors, take note. |
Pharmaceutical Executive
March 1, 2011 |
Clinical Development Outsourcing: Are We Having Fun Yet? A sneak preview of The Avoca Group's 2011 Annual Survey on CRO and Industry Relationships. |
Bio-IT World
April 2007
Deborah Borfitz |
EDC Guru Moves from Novartis to Kendle The publicly owned clinical research organization Kendle recently brought the pragmatic Sylva Collins on board to provide leadership for its global biometrics offerings and help it become "the unparalleled leader in e-clinical services." |
Pharmaceutical Executive
June 1, 2011 |
Filling in the Bigger Picture Part II of The Avoca Group's 2011 CRO survey on clinical development outsourcing relationships. |
The Motley Fool
October 23, 2009
Robert Steyer |
Taking the Drug Industry's Temperature Covance and Icon hint at broader pharmaceutical R&D trends. |
Pharmaceutical Executive
June 1, 2013 |
When Gurus Get It Wrong Despite their high status, management gurus aren't always on point when it comes to pharma, writes John Ansell. |
Bio-IT World
May 2006
Mark D. Uehling |
Bio-IT World CTMS Survey An online survey of the clinical trial management system market reveals some divergences between how the pharma/biotech folks and the contract research folks see the CTMS landscape. Are our respondents happy with the CTMS landscape? |
The Motley Fool
August 27, 2011
Michael Olsen |
Rising Star Buy: More Icon Icon shares might not appreciate tomorrow, and they might decline more before they go up. But here is a rare value: a secular growth story at a stellar valuation. |
Pharmaceutical Executive
February 1, 2011
Stergiopoulos et al. |
Honing Reforms from Clinical Development Increased efficiency and lower operating costs for both CROs and vendors can be achieved by eliminating activities |
Pharmaceutical Executive
September 1, 2008
Zhu Shen |
Unleash the Dragon Concerns over quality? It's not stopping Big Pharma outsourcing and venture capital. |
Pharmaceutical Executive
January 1, 2011
Singh & Glozman |
Managing Clinical Trials in Emerging Markets Amgen's hub-and-spoke system combines control at home with the flexibility to respond to local needs. |
Chemistry World
May 19, 2008
Hepeng Jia |
China's one stop research shop John Oyler has founded a string of startups in the US, but in 2005 he chose China as his base to launch BioDuro, a life sciences Contract Research Organisation. |
Pharmaceutical Executive
March 1, 2006
Joanna Breitstein |
Thought Leader: Q&A with Hugo Stephenson Hugo Stephenson, president of Quintiles' Strategic Research Services, offers insight into the struggles the pharmaceutical industry faces, and the solutions they're finding, to financing post-approval clinical trials. |
The Motley Fool
November 7, 2006
Brian Gorman |
Charles River Inches Forward The drug research services company is not out of the woods yet, but some positive signs are emerging. Investors, take note. |
Pharmaceutical Executive
December 1, 2010
Zhu Shen |
China 2020: Walled In No More Pharma sets the pace for China's ambitious new innovation agenda |
The Motley Fool
April 27, 2006
Brian Gorman |
PAREXEL Can Do Better Despite heartening recent results, the drug research company's profitability could be better. These shares aren't terribly cheap and it appears that investors' expectations are running high. |
CIO
November 1, 2000
Tracy Mayor |
Our Vendors, Ourselves - Interview: Frank Casale Frank Casale wants you to love your outsourcer as yourself... |
The Motley Fool
May 10, 2006
Brian Gorman |
Charles River Restructures For the near term, restructuring plans should keep this one in limbo. Investors shouldn't expect too much from the company right now. |
Bank Technology News
August 2009
John Adams |
The New Generals CROs are being charged with a broader swath of IT-related risk management. |
The Motley Fool
October 3, 2011
Brian D. Pacampara |
Pharmaceutical Product Development Shares Soared: What You Need to Know Shares of Pharmaceutical Product Development skyrocketed 25% Monday after The Carlyle Group and Hellman & Friedman LP agreed to buy the health-care research specialist for $3.8 billion. |
